Eisai Global
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Japan · 10K+ Employees
View Company Info for Free
Overview
Headquarters
4-6-10 Koishikawa Bunkyo-ku, Tokyo, Toky...Phone Number
+81 338173700Website
www.eisai.comRevenue
$5.1 BillionStock Symbol
ESAIYIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
1
1
1
1
About Eisai Global
Eisai is a global pharmaceutical manufacturing company founded in 1941. The company develops and produces medicines while focusing on a human health care approach that extends beyond traditional pharmaceutical services. Eisai operates across multiple regions including North America, Europe, Asia Pacific, and the Middle East, with a strong presence in countries such as the United States, Japan, China, and the United Kingdom. The company maintains a significant focus on research and development in the pharmaceutical sector, with particular emphasis on patient-centered healthcare solutions. Eisai's business model encompasses both business-to-business and business-to-consumer operations, reflecting its comprehensive approach to healthcare delivery and pharmaceutical development.Explore more
Eisai Global Org Chart
TB
Vice President, Commercial Neurology Franchis...
AG
Global Vice President, Regulatory Strategy Ne...
MK
Strategy Vice President, Supply Chain
KA
Vice President
SY
Vice President
SS
Vice President, China Business Japan, Asia Fi...
BW
Vice President
LO
Vice President, Quality Operations
PF
Vice President and General Manager
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Eisai Global your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Eisai Global has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Eisai Global
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Eisai Global recently announced quarterly report
Funding: Get notified immidiatlly once Eisai Global has new funding data
Product Launch: Get notified when Eisai Global launches new products
Click to see if Eisai Global had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Eisai Global, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Eisai Global is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Explore company insights
Get a deeper look into Eisai Global's structure, leadership, and market position:
Company Profile Activity
Activity Insights
Eisai Global is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Eisai Global is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Eisai Global.
Eisai Global Tech Stack
A closer look at the technologies used by Eisai Global
See more technologies
Most Recent Scoops
Open Position
Open Position
Open Position
Open Position
Open Position
Eisai Global News & Media
LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China
The First and Only Anti-Amyloid Therapy in China that Enables At-Home Administration for Alzheimer’s Disease, a Progressive Neurodegenerative Disease The First and Only Anti-Amyloid Therapy in China that Enables At-Home Administration for Alzheimer’s Disease, a Progressive Neurodegenerative DiseaseCanada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer’s Disease
An Important Step Forward for Access to LEQEMBI® for Eligible Patients in Canada An Important Step Forward for Access to LEQEMBI® for Eligible Patients in CanadaLEQEMBI IQLIK® (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer’s Disease
LEQEMBI IQLIK is the first-of-its-kind anti-amyloid treatment worldwide offering at-home dosing for initiation and maintenance (approved in the U.S.) LEQEMBI IQLIK is the first-of-its-kind anti-amyloid treatment worldwide offering at-home dosing for initiation and maintenance (approved in the U.S.)Pfizer and Eisai Commence Co-promotion of "NURTEC(R)" for the Acute Treatment and Prophylaxis (Preventive Treatment) of Migraine
TOKYO, July 27, 2026 - (JCN Newswire) - Pfizer Japan Inc. (Headquarters: Tokyo, President and Representative Director: Hiroo Igarashi,“Pfizer”) and Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the companies will commence the co-promotion of the oral calcitonin gene-related peptide (CGRP) receptor antagonist Nurtec® OD Tablet 75mg (generic name: rimegepant sulfate hydrate, hereinafter “Nurtec”) in Japan from September 1, 2026. Nurtec is an oral CGRP recept
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Eisai Global
Sign Up For FreeTo access detailed company insights
Eisai is a global pharmaceutical manufacturing company founded in 1941. The company develops and produces medicines while focusing on a human health care approach that extends beyond traditional pharmaceutical services. Eisai operates across multiple regions including North America, Europe, Asia Pacific, and the Middle East, with a strong presence... Read More
